Transforming Biologic Delivery: From Injection to Oral Administration
CuriOralRx has developed a patented oral biologics platform designed to enable the safe and effective oral delivery of peptides and proteins historically limited to injectable administration. By integrating biologic stabilization, targeted intestinal absorption, and scalable, GMP‑compatible manufacturing, the platform achieves clinically meaningful systemic exposure while preserving safety, stability, and manufacturability.
Biologic medicines—including peptides, proteins, and antibodies—have transformed the management of chronic, metabolic, pediatric, and age‑related diseases. However, most biologics still require subcutaneous or intravenous administration, creating significant challenges for long‑term therapy, patient adherence, and quality of life.
Past efforts to convert injectable biologics into oral therapies have struggled due to fundamental biological and formulation barriers, including:
The CuriOralRx platform was purpose‑built to address these constraints in an integrated and translational manner.
GRAS listed excipients preserve peptide structure during processing and protect against enzymatic degradation within the GI tract.
GRAS listed excipients preserve peptide structure during processing and protect against enzymatic degradation within the GI tract.
Together, these data demonstrate safe, reproducible systemic exposure of biologics using a platform engineered for both patient usability and commercial viability.
Therapeutic Class | Example Application | Development Stage |
GLP‑1 analogs | Metabolic disease & obesity | Preclinical |
Insulin | Diabetes | Preclinical |
Combination biologics | Metabolic disease & obesity | Preclinical |
CuriOral collaborates with biotechnology and pharmaceutical companies seeking to transform injectable biologics into oral therapies.
Engagement models include:
